<?xml version="1.0" encoding="UTF-8"?>
<item xmlns="http://omeka.org/schemas/omeka-xml/v5" itemId="403" public="1" featured="0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://omeka.org/schemas/omeka-xml/v5 http://omeka.org/schemas/omeka-xml/v5/omeka-xml-5-0.xsd" uri="https://cpw.cvlcollections.org/items/show/403?output=omeka-xml" accessDate="2026-04-05T17:14:10+00:00">
  <fileContainer>
    <file fileId="624">
      <src>https://cpw.cvlcollections.org/files/original/5d54ab6b47aebcc15557a539b0783ddb.pdf</src>
      <authentication>dc559dc9bec5133970de5d464bdfd253</authentication>
      <elementSetContainer>
        <elementSet elementSetId="4">
          <name>PDF Text</name>
          <description/>
          <elementContainer>
            <element elementId="92">
              <name>Text</name>
              <description/>
              <elementTextContainer>
                <elementText elementTextId="6795">
                  <text>The research in this publication was partially or fully funded by Colorado Parks and Wildlife.

Heather Disney Dugan, Acting Director, Colorado Parks and Wildlife • Parks and Wildlife Commission: Carrie Besnette Hauser, Chair • Dallas May, ViceChair • Marie Haskett, Secretary • Taishya Adams • Karen Michelle Bailey • Betsy Blecha • Gabriel Otero • Duke Phillips, IV • Richard Reading • James Jay
Tutchton • Eden Vardy

�Chemical immobilization in American black bears using a combination
of nalbuphine, medetomidine, and azaperone
Lisa L. Wolfe1,4, Heather E. Johnson2, Mark C. Fisher1, William R. Lance3,
David K. Smith3, and Michael W. Miller1
1

Colorado Division of Parks and Wildlife, Wildlife Health Program, 4330 Laporte Avenue, Fort Collins, CO 80521, USA
2
Colorado Division of Parks and Wildlife, 415 Turner Drive, Durango, CO 81303, USA
3
Wildlife Pharmaceuticals, Inc., 1230 Ash Street, Windsor, CO 80550, USA

Abstract: Safe and effective but unscheduled drug combinations are needed for wildlife
immobilization in some jurisdictions. To this end, we evaluated a combination of nalbuphine
HCl (40 mg/mL), medetomidine HCl (10 mg/mL), and azaperone tartrate (10 mg/mL)—referred
to as NalMed-A (or NAM)—in 28 American black bears (Ursus americanus), captured during
June to August 2014 as part of an ongoing study conducted in and around Durango, Colorado,
USA. We effectively immobilized all bears; induction (mean ¡ SE) was 16.2 ¡ 0.9 minutes
(n 5 25) and reversal was 19 ¡ 1.6 minutes (n 5 24). Advantages of NalMed-A included low
delivery volume, good sedation quality, and effective reversal. Moreover, NalMed-A does not
contain compounds regulated by the U.S. Drug Enforcement Administration, making it a useful
unscheduled immobilization combination. Based on these and subsequent field experiences, our
dosing recommendations are 0.5–1 mL NalMed-A/45.5 kg estimated body mass (0.44–0.88 mg
nalbuphine HCl/kg, 0.11–0.22 mg azaperone tartrate/kg, and 0.11–0.22 mg medetomidine
HCl/kg), and 5 mg atipamezole HCl/mg medetomidine for antagonism.
Key words: American black bear, atipamezole, azaperone, chemical immobilization, medetomidine,
nalbuphine, sedation, tranquilizer, Ursus americanus
DOI: 10.2192/URSUS-D-15-00018.1

Ursus 27(1):1–4 (2016)

Animal capture via chemical immobilization is an
important element of wildlife management and
research, including work on American black bears
(Ursus americanus). In Colorado, USA, black bears
are routinely immobilized and handled by wildlife
officers and biologists to protect public safety, resolve
human–bear conflicts, and gather data to refine population management. It follows that immobilizing drug
combinations for black bears in Colorado must be
both accessible and robust in order to perform across
a wide range of conditions, including work in urban
settings with bears that are extremely excited or agitated prior to receiving any capture drugs. These
needs and usage patterns are common among jurisdictions across North America that are managing black
bear populations.
The drug combinations most widely used for
capturing and handling black bears include dissociatives (tiletamine hydrochloride [HCl] or ketamine
HCl) or potent opioids (e.g., Bush et al. 1980, Gibeau
and Paquet 1991, Kreeger and Arnemo 2012, Kreeger

et al. 2013). In the United States, the possession and
use of these drugs—classified as “controlled substances”—are strictly regulated by the U.S. Drug
Enforcement Administration (DEA). The Veterinary
Mobility Act (2014, H.R. 1528) amended the Controlled Substances Act to allow possession and field
use of controlled substances by licensed veterinarians
registered with the DEA. Under 42 CFR section
1301.12(a), each location of storage and use requires
a separate registration, which complicates access to
and field use of capture drugs. Use of scheduled drugs
in the field is further complicated by requirements
for secure storage (21 CFR 11301.71). Severe penalties can be imposed for violating DEA rules: according to the American Veterinary Medical Association
“very few things cause more anxiety for veterinarians
in practice than the possibility of running afoul of
the DEA and Controlled Substances Act” (https://
www.avma.org/KB/Resources/Reference/Pages/dearegistration).
To meet wildlife immobilization needs in Colorado
and comply with federal rules, we have sought safe

4

email: lisa.wolfe@state.co.us

1

�2

CHEMICAL IMMOBILIZATION

IN

AMERICAN BLACK BEARS N Wolfe et al.

and effective but unscheduled alternative drug com‐
binations for wildlife work (Wolfe et al. 2014a, b).
A combination of butorphanol tartrate, azaperone
tartrate, and medetomidine HCl (BAM; Wildlife
Pharmaceuticals Inc., Fort Collins, Colorado, USA)
has been used to immobilize black bears throughout
Colorado in urban and exurban settings (Wolfe et al.
2008 and unpublished data). Although its scheduling
is lower than that of more potent opioids (Schedule
CII) or dissociatives (CIII), butorphanol is a scheduled (CIV) drug and consequently BAM is still subject to DEA oversight.
We recently described a novel combination of nalbuphine HCl, medetomidine HCl, and azaperone tartrate (NalMed-A; Wolfe et al. 2014b) that was not
subject to DEA regulations but otherwise showed
attributes similar to BAM, including safety, efficacy,
rapid antagonism, and small-volume delivery. Nalbuphine—an opiate κ agonist/m antagonist—has pharmacological properties similar to butorphanol and
produces mild analgesia and sedation with relatively
few potential adverse effects (KuKanich and Wiese
2015). However, unlike butorphanol and the more
potent opioids, abuse potential with nalbuphine
appears quite low and consequently this opioid is
not scheduled by the DEA (USDEA 2013). Medetomidine is a potent a2 adrenoceptor agonist with
sedative and analgesic properties antagonized by
atipamezole (Jalanka and Roeken 1990). Medetomidine provides smooth induction and good muscle
relaxation (Jalanka and Roeken 1990) that can be
potentiated by the effects of opioids such as nalbuphine and butorphanol (Wolfe et al. 2008, 2014b).
Azaperone—a butyrophenone—is a short-acting neuroleptic sedative that has been used to reduce stress
from capture and handling in a number of species
and can be used in combination with other drugs
to synergize effective chemical immobilization (Colly
1992, Ebedes 1992). In addition to the simplified
storage and use requirements for this drug combination, the components of NalMed-A are likely metabolized rapidly after recovery. A default withdrawal
period of 30 days has been used for BAM; however,
recent laboratory analyses did not detect butorphanol, azaperone, medetomidine, or atipamezole in liver
or muscle of white-tailed deer (Odocoileus virginianus)
after 11 days (W.R. Lance, unpublished data).
A similar withdrawal time would be expected with
NalMed-A.
To further our efforts to identify broadly useful,
wildlife-immobilizing drug combinations that are

safe and effective but unscheduled, we evaluated
the field use of NalMed-A for chemical immobilization in black bears.

Methods
During June to August 2014, we immobilized
25 adult, free-ranging black bears (17 M, 8 F) as
part of an ongoing study (Johnson et al. 2011; Colorado Division of Parks and Wildlife Animal Care and
Use Committee file no. 01-2011) conducted in and
around the town of Durango, Colorado, USA (elevation approx. 2,000 m above sea level), as well as
3 bears that were being relocated or euthanized as a
result of human conflict.
The NalMed-A components were premixed in a single vial for ease of field use. The NalMed-A solution
had final concentrations of 40 mg nalbuphine HCl/
mL, 10 mg azaperone tartrate/mL, and 10 mg medetomidine HCl/mL. We initially extrapolated dosing
from previous experience with BAM in .200 black
bears (Wolfe et al. 2008 and unpublished data) and
therefore used 1 mL NalMed-A/45.5 kg body mass
for estimated dosages of 0.88 mg nalbuphine HCl/
kg, 0.22 mg azaperone tartrate/kg, and 0.22 mg medetomidine HCl/kg.
We captured 23 research bears in cage traps and
delivered drugs via intramuscular injection with
a pole syringe (DAN-INJECT, Børkop, Denmark);
2 of the conflict bears were captured in culvert traps,
and the remaining 3 bears were darted with CO2powered rifles (DAN-INJECT). We avoided injection placement in fat pads to insure consistent drug
absorption. We visually estimated body mass for
dosing, and we then weighed immobilized animals
using a suspended scale to calculate actual dosages
used. We measured induction as the time lapsed
from NalMed-A injection until sternal recumbency
or head down and unresponsive to stimuli (i.e.,
when we considered the bear as safe to handle).
Once the animal was immobilized, we took studyspecific biometrics, blood via femoral venopuncture,
and one or more sets of vital signs. We measured heart
rate with a pulse oximeter (SurgiVet V3402; Smiths
Medical PM, Inc., Waukesha, Wisconsin, USA) or
via cardiac auscultation with a stethoscope. We measured respiration by observation of chest movement.
We measured rectal temperature with a digital
thermometer (FlashCheck; DeltaTrak, Pleasanton,
California, USA). Although we used a pulse oximeter,
oxygen saturation was monitored but not consistently
Ursus 27(1):1–4 (2016)

�CHEMICAL IMMOBILIZATION
recorded under field conditions, in part because we
routinely supplemented oxygen at 2 L/minute with
an intransal canula (Roscoe Medical, Strongsville,
Ohio, USA) to assure SpO2 remained $90%. We
monitored vital rates approximately every 10 minutes
throughout the handling period. We fitted 8 adult
female bears with radiocollars, and we monitored
their posthandling survival for $6 months (as part of
the ongoing survival study). We marked the remaining bears with ear-tags or transponder tags so they
could be identified if recaptured or encountered as a
mortality. We antagonized medetomidine with intramuscular injection of atipamezole HCl (5 mg/mg
medetomidine HCl; Wildlife Pharmaceuticals, Inc.).
We measured reversal as time lapsed from atipamezole injection until the animal was able to stand.
We used mixed-effect models to estimate mean vital
rates throughout the handling period. The fixed
effect was an intercept-only model (to estimate mean
values) and the random effect was individual bear,
accounting for repeated measurements of the same
animal taken during the handling process. We fit
models with the package lme4 (Bates et al. 2013) using
Program R (version 3.0.2; R Development Core
Team 2013).

Results
All 28 black bears were successfully immobilized
with the NalMed-A combination. The mean measured body mass of the bears was 66 kg (standard
error [SE] 5 5, range 5 21–115 kg) and the mean
volume delivered was 1.4 mL (SE 5 0.1), equating
to mean dosages of 0.8 mg/kg (SE 5 0.3) nalbuphine
HCl, 0.2 mg/kg (SE 5 0. 01) azaperone tartrate,
and 0.2 mg/kg (SE 5 0.01) medetomidine HCl.
Mean induction was 16.2 minutes (n 5 25, SE 5 0.9,
range 5 10–26 min). We considered quality of sedation to be good in all bears based on our ability
to safely handle and sample the animals throughout
the processing period (�x 5 40 min, SE 5 3, range 5
18–67 min). Only 3 bears required a supplemental
dose (one-quarter of original dose) of NalMed-A for
complete immobilization.
Based on vital-rate measurements of 25 bears
taken throughout the immobilization period, mean
respiratory rate was 7 breaths/minute (SE , 1, range
5 5–14), mean heart rate was 40 beats/minute
(SE 5 2, range 5 30–58), and mean rectal temperature was 38.3uC (SE 5 0.1, range 5 37.3–39.7uC).
Mean reversal time was 19 minutes (n 5 24, SE 5 2,
Ursus 27(1):1–4 (2016)

IN

AMERICAN BLACK BEARS N Wolfe et al.

3

range 5 7–36 min) after administration of intramuscular atipamezole. Bears were ambulatory and
responsive but calm on reversal because only medetomidine was antagonized and nalbuphine and azaperone were still on board. Except for the 2 bears that
were euthanized because of conflicts, we observed no
mortalities within 1 week after release, and survival
of telemetered bears was equivalent to that of other
bears monitored during the Durango study (H.E.
Johnson, unpublished data).

Discussion
Beneficial properties of NalMed-A as a chemical
immobilization combination included low volume of
delivery, good quality of sedation, and effective reversal. From our initial field assessments, NalMed-A
appears to be an effective drug combination for
immobilizing trapped or treed black bears. Moreover,
in situations where use of scheduled drugs is precluded or unreasonably constrained by regulatory
compliance, such as when used in the field by nonveterinary personnel, this combination offers the benefit of being unscheduled. Overall, the immobilization
properties of NalMed-A in bears were similar to
our experiences with BAM (Wolfe et al. 2008 and
unpublished data). The concentration of NalMed-A
allowed us to use a relatively low total drug volume
for sedation (,2 mL for most individuals) that could
be easily delivered with either a pole syringe or dart.
We regarded the quality of sedation as sufficient for
safe handling and sampling (e.g., blood draw, ear
tag, and radiocollar placement). Three bears required
supplemental NalMed-A for adequate immobilization, likely because their mass was underestimated.
Unlike dissociatives, this combination is reversible
with atipamezole alone, providing a smooth recovery.
Although not used with these bears, nalbuphine can
be antagonized with naltrexone (0.6 mg/kg; Wildlife
Pharmaceuticals, Inc.), which may speed the rate of
recovery.
Bears immobilized with NalMed-A showed respiratory rate depression similar to that reported for other
drug combinations (Caulkett and Cattet 1997, Wolfe
et al. 2008, Kreeger et al. 2013). Consequently, we
recommend using supplemental oxygen when immobilizing black bears with NalMed-A. In addition,
care should be taken to give intramuscular injections
because medetomidine HCl is lipophilic and absorption from fat pads will be slow. In order to maximize
the effectiveness of NalMed-A (and BAM)

�4

CHEMICAL IMMOBILIZATION

IN

AMERICAN BLACK BEARS N Wolfe et al.

immobilization in black bears, we preferentially use
injection sites in the shoulder or leg and avoid injecting into the back or rump. Although not observed in
the bears we immobilized, spontaneous arousal (Kreeger and Arnemo 2012) could occur in bears immobilized with NalMed-A.
We recognize that medetomidine dosage reported
here is relatively high compared with that in other combinations used to immobilize black bears (e.g., Wolfe
et al. 2008, Kreeger and Arnemo 2012). Black bears
can be effectively immobilized with 0.5 mL NalMedA/45.5 kg body mass (L.L. Wolfe, unpublished data),
delivering a medetomidine dose (approx. 0.11 mg
HCl/kg) similar to that originally described for butorphanol–azaperone–medetomidine (Wolfe et al. 2008).
However, the occasional need for supplemental injections when using lower NalMed-A doses made this
less well-suited for the circumstances in which our officers typically operated, and thus we sought to err on
the side of a dosage that would result in a high probability of effective immobilization with a single administration. Based on initial observations, NalMed-A appears
to be a promising drug combination for immobilizing
bears and warrants further evaluation.

Acknowledgments
Our work was funded by Colorado Parks and
Wildlife, with NalMed-A generously provided by
Wildlife Pharmaceuticals, Inc. We also thank the Editor, Associate Editor, and 2 anonymous reviewers for
providing helpful comments on earlier versions of our
manuscript.

Literature cited
BATES, D., M. MAECHLER, B. BOLKER, AND S. WALKER.
2013. lme4: Linear mixed-effects models using Eigen
and S4. R package version 1.0-5. http://CRAN.Rproject.org/package5lme4. Accessed 12 Nov 2015.
BUSH, M., R.S. CUSTER, AND E.E. SMITH. 1980. Use of
dissociative anesthetics for the immobilization of captive
bears: Blood gas, hematology and biochemistry values.
Journal of Wildlife Diseases 16:481–489.
CAULKETT, N.A., AND M.R. CATTET. 1997. Physiological
effects of medetomidine–zolazepam–tiletamine immobilization in black bears. Journal of Wildlife Diseases
33:618–622.
COLLY, L.P. 1992. Azaperone—A safe and well-tried
tranquilizer. Pages 21–22 in E. Ebedes, editor. The
use of tranquilizers in wildlife. Department of Agricultural Development Bulletin No. 423, Pretoria, Gauteng
Province, South Africa.

EBEDES, H. 1992. A note on haloperidol for translocation.
Pages 23–24 in E. Ebedes, editor. The use of tranquilizers
in wildlife. Department of Agricultural Development Bulletin No. 423, Pretoria, Gauteng Province, South Africa.
GIBEAU, M.L., AND P.C. PAQUET. 1991. Evaluation of
TelazolH for immobilization of black bears. Wildlife
Society Bulletin 19:400–402.
JALANKA, H.H., AND B.O. ROEKEN. 1990. The use of medetomidine, medetomidine–ketamine combinations, and
atipamezole in nondomestic mammals: A review. Journal of Zoo and Wildlife Medicine 21:259–282.
JOHNSON, H.E., C.J. BISHOP, M.W. ALLDREDGE, J. BRODRICK,
J. APKER, S. BRECK, K. WILSON, AND J. BECKMANN. 2011.
Black bear exploitation of urban environments: Finding
management solutions and assessing regional population
effects. Colorado Division of Parks and Wildlife Research
Proposal, Fort Collins, Colorado, USA.
KREEGER, T.J., AND J.M. ARNEMO. 2012. Handbook of wildlife chemical immobilization. Fourth edition. T. Kreeger
(published by author).
———, D. BJORNLIE, D. THOMPSON, J. CLAPP, C. CLARK, C.
HANSEN, M. JUIZENGA, AND S. LOCKWOOD. 2013. Immobilization of Wyoming bears using carfentanil and xylazine. Journal of Wildlife Diseases 49:674–678.
KUKANICH, B., AND A.J. WIESE. 2015. Opioids. Pages 207–
226 in K.A. Grimm, L.A. Lamont, W.J. Tranquilli, S.A.
Green, and S.A. Robertson, editors. Veterinary anesthesia and analgesia: The fifth edition of Lumb and Jones.
Wiley Blackwell, Ames, Iowa, USA.
R DEVELOPMENT CORE TEAM. 2013. R: A language and
environment for statistical computing. R Foundation
for Statistical Computing, Vienna, Austria. http://www.
R-project.org/. Accessed 12 Nov 2016.
U.S. DRUG ENFORCEMENT ADMINISTRATION. 2013. Nalbuphine
hydrochloride. Drug information summary. http://www.
deadiversion.usdoj.gov/drug_chem_info/nalbuphine.pdf.
Accessed 12 Nov 2016.
WOLFE, L.W., C.T. GOSHORN, AND S. BARACH-MORDO.
2008. Immobilization of black bears (Ursus americanus)
with a combination of butorphanol, azaperone, and
medetomidine. Journal of Wildlife Diseases 44:748–752.
———, H.E. JOHNSON, M.C. FISHER, M.A. SIROCHMAN, B.
KRAFT, AND M.W. MILLER. 2014a. Use of acepromazine
and medetomidine in combination for sedation and
handling of Rocky Mountain elk (Cervus elaphus nelsoni)
and black bears (Ursus americanus). Journal of Wildlife
Diseases 44:979–981.
———, W.R. LANCE, D.K. SMITH, AND M.W. MILLER.
2014b. Novel combinations of nalbuphine and medetomidine for wildlife immobilization. Journal of Wildlife
Diseases 50:951–956.

Received: 15 June 2015
Accepted: 18 December 2015
Associate Editor: Waller
Ursus 27(1):1–4 (2016)

�</text>
                </elementText>
              </elementTextContainer>
            </element>
          </elementContainer>
        </elementSet>
      </elementSetContainer>
    </file>
  </fileContainer>
  <collection collectionId="2">
    <elementSetContainer>
      <elementSet elementSetId="1">
        <name>Dublin Core</name>
        <description>The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.</description>
        <elementContainer>
          <element elementId="50">
            <name>Title</name>
            <description>A name given to the resource</description>
            <elementTextContainer>
              <elementText elementTextId="479">
                <text>Journal Articles</text>
              </elementText>
            </elementTextContainer>
          </element>
          <element elementId="41">
            <name>Description</name>
            <description>An account of the resource</description>
            <elementTextContainer>
              <elementText elementTextId="7018">
                <text>CPW peer-reviewed journal publications</text>
              </elementText>
            </elementTextContainer>
          </element>
        </elementContainer>
      </elementSet>
    </elementSetContainer>
  </collection>
  <itemType itemTypeId="1">
    <name>Text</name>
    <description>A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.</description>
  </itemType>
  <elementSetContainer>
    <elementSet elementSetId="1">
      <name>Dublin Core</name>
      <description>The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.</description>
      <elementContainer>
        <element elementId="50">
          <name>Title</name>
          <description>A name given to the resource</description>
          <elementTextContainer>
            <elementText elementTextId="6796">
              <text>Chemical immobilization in American black bears using a combination of nalbuphine, medetomidine, and azaperone</text>
            </elementText>
          </elementTextContainer>
        </element>
        <element elementId="41">
          <name>Description</name>
          <description>An account of the resource</description>
          <elementTextContainer>
            <elementText elementTextId="6797">
              <text>Safe and effective but unscheduled drug combinations are needed for wildlife immobilization in some jurisdictions. To this end, we evaluated a combination of nalbuphine HCl (40 mg/mL), medetomidine HCl (10 mg/mL), and azaperone tartrate (10 mg/mL)—referred to as NalMed-A (or NAM)—in 28 American black bears (Ursus americanus), captured during June to August 2014 as part of an ongoing study conducted in and around Durango, Colorado, USA. We effectively immobilized all bears; induction (mean ¡ SE) was 16.2 ¡ 0.9 minutes (n 5 25) and reversal was 19 ¡ 1.6 minutes (n 5 24). Advantages of NalMed-A included low delivery volume, good sedation quality, and effective reversal. Moreover, NalMed-A does not contain compounds regulated by the U.S. Drug Enforcement Administration, making it a useful unscheduled immobilization combination. Based on these and subsequent field experiences, our dosing recommendations are 0.5–1 mL NalMed-A/45.5 kg estimated body mass (0.44–0.88 mg nalbuphine HCl/kg, 0.11–0.22 mg azaperone tartrate/kg, and 0.11–0.22 mg medetomidine HCl/kg), and 5 mg atipamezole HCl/mg medetomidine for antagonism.</text>
            </elementText>
          </elementTextContainer>
        </element>
        <element elementId="80">
          <name>Bibliographic Citation</name>
          <description>A bibliographic reference for the resource. Recommended practice is to include sufficient bibliographic detail to identify the resource as unambiguously as possible.</description>
          <elementTextContainer>
            <elementText elementTextId="6798">
              <text>Wolfe, L. L., H. E. Johnson, M. C. Fisher, W. R. Lance, D. K. Smith, and M. W. Miller. 2016. Chemical immobilization in American black bears using a combination of nalbuphine, medetomidine, and azaperone. Ursus 27:1–4. https://doi.org/10.2192/URSUS–D–15–00018.1</text>
            </elementText>
          </elementTextContainer>
        </element>
        <element elementId="39">
          <name>Creator</name>
          <description>An entity primarily responsible for making the resource</description>
          <elementTextContainer>
            <elementText elementTextId="6799">
              <text>Wolfe, Lisa L.</text>
            </elementText>
            <elementText elementTextId="6800">
              <text>Johnson, Heather E.</text>
            </elementText>
            <elementText elementTextId="6801">
              <text>Fisher, Mark C.</text>
            </elementText>
            <elementText elementTextId="6802">
              <text>Lance, William R.</text>
            </elementText>
            <elementText elementTextId="6803">
              <text>Smith, David K.</text>
            </elementText>
            <elementText elementTextId="6804">
              <text>Miller, Michael W.</text>
            </elementText>
          </elementTextContainer>
        </element>
        <element elementId="49">
          <name>Subject</name>
          <description>The topic of the resource</description>
          <elementTextContainer>
            <elementText elementTextId="6805">
              <text>Black bear</text>
            </elementText>
            <elementText elementTextId="6806">
              <text>Atipamezole</text>
            </elementText>
            <elementText elementTextId="6807">
              <text>Azaperone</text>
            </elementText>
            <elementText elementTextId="6808">
              <text>Chemical immobilization</text>
            </elementText>
            <elementText elementTextId="6809">
              <text>Medetomidine</text>
            </elementText>
            <elementText elementTextId="6810">
              <text>Sedation</text>
            </elementText>
            <elementText elementTextId="6811">
              <text>Tranquilizer</text>
            </elementText>
          </elementTextContainer>
        </element>
        <element elementId="78">
          <name>Extent</name>
          <description>The size or duration of the resource.</description>
          <elementTextContainer>
            <elementText elementTextId="6812">
              <text>4 pages</text>
            </elementText>
          </elementTextContainer>
        </element>
        <element elementId="47">
          <name>Rights</name>
          <description>Information about rights held in and over the resource</description>
          <elementTextContainer>
            <elementText elementTextId="6813">
              <text>&lt;a href="http://rightsstatements.org/vocab/InC-NC/1.0/"&gt;IN COPYRIGHT - NON-COMMERCIAL USE PERMITTED&lt;/a&gt;</text>
            </elementText>
          </elementTextContainer>
        </element>
        <element elementId="42">
          <name>Format</name>
          <description>The file format, physical medium, or dimensions of the resource</description>
          <elementTextContainer>
            <elementText elementTextId="6815">
              <text>application/pdf</text>
            </elementText>
          </elementTextContainer>
        </element>
        <element elementId="44">
          <name>Language</name>
          <description>A language of the resource</description>
          <elementTextContainer>
            <elementText elementTextId="6816">
              <text>English</text>
            </elementText>
          </elementTextContainer>
        </element>
        <element elementId="70">
          <name>Is Part Of</name>
          <description>A related resource in which the described resource is physically or logically included.</description>
          <elementTextContainer>
            <elementText elementTextId="6817">
              <text>Ursus</text>
            </elementText>
          </elementTextContainer>
        </element>
        <element elementId="57">
          <name>Date Accepted</name>
          <description>Date of acceptance of the resource. Examples of resources to which a Date Accepted may be relevant are a thesis (accepted by a university department) or an article (accepted by a journal).</description>
          <elementTextContainer>
            <elementText elementTextId="6818">
              <text>12/18/2015</text>
            </elementText>
          </elementTextContainer>
        </element>
        <element elementId="60">
          <name>Date Issued</name>
          <description>Date of formal issuance (e.g., publication) of the resource.</description>
          <elementTextContainer>
            <elementText elementTextId="6819">
              <text>05/01/2016</text>
            </elementText>
          </elementTextContainer>
        </element>
        <element elementId="59">
          <name>Date Submitted</name>
          <description>Date of submission of the resource. Examples of resources to which a Date Submitted may be relevant are a thesis (submitted to a university department) or an article (submitted to a journal).</description>
          <elementTextContainer>
            <elementText elementTextId="6820">
              <text>06/15/2015</text>
            </elementText>
          </elementTextContainer>
        </element>
        <element elementId="51">
          <name>Type</name>
          <description>The nature or genre of the resource</description>
          <elementTextContainer>
            <elementText elementTextId="7026">
              <text>Article</text>
            </elementText>
          </elementTextContainer>
        </element>
      </elementContainer>
    </elementSet>
  </elementSetContainer>
</item>
